The investment team discuss news in the sector during the year. They give a new update on vaccine development against COVID-19 and the mutation discovered recently. The fund´s performance has been solid in 2020 both on an absolute and relative basis. The best performing companies in the portfolio with their drug candidates or theraputic treatment are discussed as well as some companies which haven´t performed that well. Big Pharma is focusing more and more on rare diseases and some cases here are discussed. At the end of the video they give some highlights from the The American Society of Hematology (ASH) annual scientific conference in December. Finally, they share some thoughts on the outlook for 2021.